FLT3-IN-40 

FLT3-IN-40 (compound 1) is a type I ATP-competitive FLT3 inhibitor with an IC₅₀ of 16.26 nM. FLT3-IN-40 reduces the autophosphorylation level of FLT3 and the phosphorylation level of downstream ERK. FLT3-IN-40 exhibits antiproliferative, cell cycle regulatory and apoptosis-inducing activities. FLT3-IN-40 can be used in research related to acute myeloid leukemia^[1].

FLT3-IN-40 (compound 1) (0.00001-100 nM; sufficient to measure antiproliferative effects) potently inhibits MV4-11 cell proliferation with an IC₅₀ of 0.002 nM, exhibiting a gradual, biphasic dose-response profile^[1].
FLT3-IN-40 (0.001-10 nM) is an ATP-competitive type-I FLT3 inhibitor, inhibiting purified FLT3 kinase with an IC₅₀ of 16.26 nM and MV4-11 cellular FLT3 pathway signaling with an IC₅₀ of 0.80 nM for p-ERK inhibition^[1].
FLT3-IN-40 (sufficient to measure antiproliferative effects) inhibits Molm14 cell proliferation with an IC₅₀ of 1.42 nM, and has much weaker antiproliferative activity against K562 (IC₅₀ 1583 nM) and Ba/F3 (IC₅₀ 8467 nM) cells lacking FLT3 activating mutations^[1].
FLT3-IN-40 (1 pM-10 nM; 72 h) induces minimal apoptosis in MV4-11 cells at picomolar concentrations, but triggers significant early (17.3%) and late (10.3%) apoptosis at 10 nM following 72 h of treatment^[1].
FLT3-IN-40 (1 pM-10 nM; 72 h) induces a moderate G₁ phase stabilization in MV4-11 cells at picomolar concentrations, and a strong G₁ phase cell cycle arrest at 10 nM following 72 h of treatment^[1].
FLT3-IN-40 (1 nM; 10 nM) exhibits high kinase selectivity, with strong binding only to FLT3 among the 96 kinases tested at 1 nM and 10 nM concentrations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

426.47

C₂₄H₂₂N₆O₂

3075541-07-7

COC1=CC(OC)=C(C=C1)NC2=CC=CC(C3=CN=C4C=C(C=CN34)C5=CN(N=C5)C)=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang X, et al. An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition. Bioorg Chem. 2026;173:109601.  [Content Brief]